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Recommended Pediatric Immunization Schedules — United States - 2017
Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2017. 
(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). 
These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. 
To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos
19-23 
mos
2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13-15 yrs 16 yrs 17-18 yrs
Hepatitis B1  (HepB)
Rotavirus2  (RV) RV1 (2-dose 
series); RV5 (3-dose series)
Diphtheria, tetanus, & acellular 
pertussis3  (DTaP: <7 yrs)
Haemophilus influenzae type b4 
(Hib)
Pneumococcal conjugate5 
(PCV13)
Inactivated poliovirus6 
(IPV: <18 yrs)
Influenza7  (IIV) 
Measles, mumps, rubella8  (MMR)
Varicella9  (VAR)
Hepatitis A1 0  (HepA) 
Meningococcal1 1  (Hib-MenCY  
>6 weeks; MenACWY-D >9 mos; 
MenACWY-CRM ≥2 mos) 
Tetanus, diphtheria, & acellular 
pertussis1 2  (Tdap: >7 yrs)
Human papillomavirus1 3  (HPV)
Meningococcal B1 1
Pneumococcal polysaccharide5 
(PPSV23)
2nd dose1st doseSee footnote 11
See footnote 
13
Annual vaccination (IIV) 1 or 2 doses
See footnote 5
Tdap
See 
footnote 22
nd dose1st dose
4th dose3rd dose2nd dose1st dose
2-dose series, See footnote 10
4th dose3rd dose2nd dose1st dose
2nd dose1st dose
3rd or 4th dose, 
See footnote 4
See 
footnote 42
nd dose1st dose
2nd dose1st dose
5th dose4th dose3rd dose2nd dose1st dose
3rd dose2nd dose1st dose
Annual vaccination (IIV)  
1 dose only
See footnote 8
See footnote 11
No recommendationRange of recommended ages  
for certain high-risk  groups
Range of recommended 
ages for all children
Range of recommended ages 
for catch-up immunization
Range of recommended ages for non-high-risk 
groups that may receive vaccine, subject to 
individual clinical decision making
FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind—United States, 2017.
The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between 
doses. Use the section appropriate for the child’s age. Always use this table in conjunction with Figure 1 and the footnotes that follow.
Children age 4 months through 6 years
Vaccine
Minimum 
Age for 
Dose 1
Minimum Interval Between Doses
Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5
Hepatitis B1 Birth 4 weeks
8 weeks 
and at least 16 weeks after first dose. 
Minimum age for the final dose is 24 weeks.
Rotavirus2 6 weeks 4 weeks 4 weeks2
Diphtheria, tetanus, and 
acellular pertussis3 6 weeks 4 weeks 4 weeks 6 months 6 months
3
Haemophilus influenzae 
type b4 6 weeks
4 weeks 
if first dose was administered before the 1st 
birthday.
8 weeks (as final dose) 
if first dose was administered at age 12 
through 14 months.
No further doses needed if first dose was 
administered at age 15 months or older.
4 weeks4 
if current age is younger than 12 months and first dose was administered at younger 
than age 7 months, and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or 
unknown.
8 weeks 
and age 12 through 59 months (as final dose)4 
• if current age is younger than 12 months  
and first dose was administered at age 7 through 11 months; 
OR
• if current age is 12 through 59 months  
and first dose was administered before the 1st birthday, and second dose adminis-
tered at younger than 15 months;  
OR
• if both doses were PRP-OMP (PedvaxHIB; Comvax)  
and were administered before the 1st birthday.
No further doses needed 
if previous dose was administered at age 15 months or older.
8 weeks (as final dose) 
This dose only necessary for children age 12 
through 59 months who received 3 doses 
before the 1st birthday.
Pneumococcal5 6 weeks
4 weeks 
if first dose administered before the 1st 
birthday.
8 weeks (as final dose for healthy children)
if first dose was administered at the 1st 
birthday or after.
No further doses needed 
for healthy children if first dose was admin-
istered at age 24 months or older.
4 weeks 
if current age is younger than 12 months and previous dose given at <7 months old.
8 weeks (as final dose for healthy children) 
if previous dose given between 7-11 months (wait until at least 12 months old); 
OR
if current age is 12 months or older and at least 1 dose was given before age 12 months.
No further doses needed for healthy children if previous dose administered at age 24 
months or older.
8 weeks (as final dose) 
This dose only necessary for children aged 
12 through 59 months who received 3 doses 
before age 12 months or for children at high 
risk who received 3 doses at any age.
Inactivated poliovirus6 6 weeks 4 weeks6 4 weeks6 6 months6 (minimum age 4 years for final dose).
Measles, mumps, rubella8 12 months 4 weeks
Varicella9 12 months 3 months
Hepatitis A10 12 months 6 months
Meningococcal11
(Hib-MenCY ≥6 weeks; 
MenACWY-D ≥9 mos;
MenACWY-CRM ≥2 mos)
6 weeks 8 weeks11 See footnote 11 See footnote 11
Children and adolescents age 7 through 18 years
Meningococcal11
(MenACWY-D ≥9 mos;
MenACWY-CRM ≥2 mos)
Not Applicable 
(N/A) 8 weeks
11 
Tetanus, diphtheria; 
tetanus, diphtheria, and 
acellular pertussis12
7 years12 4 weeks 
4 weeks 
if first dose of DTaP/DT was administered before the 1st birthday. 
6 months (as final dose) 
if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.
6 months if first dose of DTaP/DT  was 
administered before the 1st birthday.
Human papillomavirus13 9 years Routine dosing intervals are recommended.13
Hepatitis A10 N/A 6 months
Hepatitis B1 N/A 4 weeks 8 weeks and at least 16 weeks after first dose.
Inactivated poliovirus6 N/A 4 weeks 4 weeks6 6 months6
Measles, mumps, rubella8 N/A 4 weeks
Varicella9 N/A 3 months if younger than age 13 years. 4 weeks if age 13 years or older.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
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For more information visit:
www.scdhec.gov/scimmunize
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2017 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the ACIP General 
Recommendations on Immunization and the relevant ACIP statement, available online at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
• Vaccine doses administered ≤4 days before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not 
be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see 
Table 1, Recommended and minimum ages and intervals between vaccine doses, in MMWR, General Recommendations on Immunization and Reports / Vol. 60 / No. 2, available online at www.cdc.gov/
mmwr/pdf/rr/rr6002.pdf.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, Vaccination of persons with primary and secondary immunodeficiencies, in General Recommendations 
on Immunization (ACIP), available at www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and Immunization in Special Clinical Circumstances, (American Academy of Pedatrics). In: Kimberlin DW, Brady MT, 
Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015:68-107.
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury petitions. Created by the National Childhood Vaccine 
Injury Act of 1986, it provides compensation to people found to be injured by certain vaccines. All vaccines within the recommended childhood immunization schedule are covered by VICP 
except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/index.html.
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
• Administer monovalent HepB vaccine to all newborns 
within 24 hours of birth.
• For infants born to hepatitis B surface antigen (HBsAg)-
positive mothers, administer HepB vaccine and 0.5 mL 
of hepatitis B immune globulin (HBIG) within 12 hours 
of birth. These infants should be tested for HBsAg and 
antibody to HBsAg (anti-HBs) at age 9 through 12 months 
(preferably at the next well-child visit) or 1 to 2 months 
after completion of the HepB series if the series was 
delayed.
• If mother’s HBsAg status is unknown, within 12 hours of 
birth, administer HepB vaccine regardless of birth weight. 
For infants weighing less than 2,000 grams, administer 
HBIG in addition to HepB vaccine within 12 hours of birth. 
Determine mother’s HBsAg status as soon as possible 
and, if mother is HBsAg-positive, also administer HBIG to 
infants weighing 2,000 grams or more as soon as possible, 
but no later than age 7 days.
Doses following the birth dose:
• The second dose should be administered at age 1 or 2 
months. Monovalent HepB vaccine should be used for 
doses administered before age 6 weeks.
• Infants who did not receive a birth dose should receive 3 
doses of a HepB-containing vaccine on a schedule of 0, 
1 to 2 months, and 6 months, starting as soon as feasible 
(see figure 2).
• Administer the second dose 1 to 2 months after the first 
dose (minimum interval of 4 weeks); administer the third 
dose at least 8 weeks after the second dose AND at least 
16 weeks after the first dose. The final (third or fourth) 
dose in the HepB vaccine series should be administered 
no earlier than age 24 weeks.
• Administration of a total of 4 doses of HepB vaccine is 
permitted when a combination vaccine containing HepB 
is administered after the birth dose. 
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose series.
• A 2-dose series (doses separated by at least 4 months) of 
adult formulation Recombivax HB is licensed for use in 
children aged 11 through 15 years. 
• For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both 
RV1 [Rotarix] and RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, administer a 2-dose series at ages 2 
and 4 months. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 
4, and 6 months. 
3. If any dose in the series was RotaTeq or vaccine product 
is unknown for any dose in the series, a total of 3 doses 
of RV vaccine should be administered. 
Catch-up vaccination:
• The maximum age for the first dose in the series is 14 
weeks, 6 days; vaccination should not be initiated for 
infants aged 15 weeks, 0 days, or older.
• The maximum age for the final dose in the series is 8 
months, 0 days.
• For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis 
(DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-
IPV [Kinrix, Quadracel]: 4 years)
Routine vaccination:
• Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 
15 through 18 months, and 4 through 6 years.  The fourth 
dose may be administered as early as age 12 months, 
provided at least 6 months have elapsed since the third 
dose.
• Inadvertent administration of fourth DTaP dose early:  
If the fourth dose of DTaP was administered at least 4 
months after the third dose of DTaP and the child was 12 
months of age or older, it does not need to be repeated.
Catch-up vaccination:
• The fifth dose of DTaP vaccine is not necessary if the 
fourth dose was administered at age 4 years or older.
• For other catch-up guidance, see Figure 2.
4. Haemophilus influenzae type b (Hib) conjugate vaccine.  
(Minimum age:  6 weeks for PRP-T [ActHIB, DTaP-IPV/Hib 
(Pentacel), Hiberix, and Hib-MenCY (MenHibrix)], PRP-
OMP [PedvaxHIB]) 
Routine vaccination:
• Administer a 2- or 3-dose Hib vaccine primary series 
and a booster dose (dose 3 or 4, depending on vaccine 
used in primary series) at age 12 through 15 months to 
complete a full Hib vaccine series.
• The primary series with ActHIB, MenHibrix, Hiberix, 
or Pentacel consists of 3 doses and should be 
administered at ages 2, 4, and 6 months. The primary 
series with PedvaxHIB consists of 2 doses and should be 
administered at ages 2 and 4 months; a dose at age 6 
months is not indicated.
• One booster dose (dose 3 or 4, depending on vaccine 
used in primary series) of any Hib vaccine should be 
administered at age 12 through 15 months. 
• For recommendations on the use of MenHibrix in patients 
at increased risk for meningococcal disease, refer to the 
meningococcal vaccine footnotes and also to MMWR 
February 28, 2014 / 63(RR01):1-13, available at www.cdc.
gov/mmwr/PDF/rr/rr6301.pdf.
Footnotes — Recommended Immunization Schedule for Childr n a d Adole cent  Aged 18 Years or Younger, UNITED STATES, 2017 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.ht l.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the ACIP General 
Recommendations on Immunization and the relevant ACIP statement, available online at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
• Vaccine doses administered ≤4 days before the minimum interval are considered valid. Doses of any vaccine a ministered ≥5 days earlier than the minimum interval or minimum age should not 
be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see 
Table 1, Recommended and minimum ages and intervals between vacci e doses, in MMWR, General Recommendati ns on Immunization and Reports / Vol. 60 / No. 2, available online at www.cdc.gov/
mmwr/pdf/rr/rr6002.pdf.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, Vaccination of persons with primary and secondary immunodeficiencies, in General Recommendations 
on Immunization (ACIP), available at www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and Immunizati n in Special Clinical Circumstances, (American Academy of Pedatrics). In: Kimberlin DW, Brady MT, 
Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015:68-107.
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury petitions. Created by the National Childhood Vaccine 
Injury Act of 1986, it provides compensation to people found to be injured by certain vaccines. All vacci es within the recommended childhood immunization schedule are covered by VICP 
except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompe sation/index.html.
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
• Administer monovalent HepB vaccine to all newborns 
within 24 hours of birth.
• For infants born to hepatitis B surface antigen (HBsAg)-
positive mothers, administer HepB vaccine and 0.5 mL 
of hepatitis B immune globulin (HBIG) within 12 hours 
of birth. These infants should be tested for HBsAg and 
antibody to HBsAg (anti-HBs) at age 9 through 12 months 
(preferably at the next well-child visit) or 1 to 2 months 
after completion of the HepB series if the series was 
delayed.
• If mother’s HBsAg status is unknown, within 12 hours of 
birth, administer HepB vaccine regardless of birth weight. 
For infants weighing less than 2,000 grams, administer 
HBIG in addition to HepB vaccine within 12 hours of birth. 
Determine mother’s HBsAg status as soon as possible 
and, if mother is HBsAg-positive, also administer HBIG to 
infants weighing 2,000 grams or more as soon as possible, 
but no later than age 7 days.
Doses following the birth dose:
• The second dose should be administered at age 1 or 2 
months. Monovalent HepB vaccine should be used for 
doses administered before age 6 weeks.
• Infants who did not receive a birth dose should receive 3 
doses of a HepB-containing vaccine on a schedule of 0, 
1 to 2 months, and 6 months, starting as soon as feasible 
(see figure 2).
• Administer the second dose 1 to 2 months after the first 
dose (minimum interval of 4 weeks); administer the third 
dose at least 8 weeks after the second dose AND at least 
16 weeks after the first dose. The final (third or fourth) 
dose in the HepB vaccine series should be administered 
no earlier than age 24 weeks.
• Administration of a total of 4 doses of HepB vaccine is 
permitted when a combination vaccine containing HepB 
is administered after the birth dose. 
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose series.
• A 2-dose series (doses separated by at least 4 months) of 
adult formulation Recombivax HB is licensed for use in 
children aged 11 through 15 years. 
• For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both 
RV1 [Rotarix] and RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, administer a 2-dose series at ages 2 
and 4 months. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 
4, and 6 months. 
3. If any dose in the series was RotaTeq or vaccine product 
is unknown for any dose in the series, a total of 3 doses 
of RV vaccine should be administered. 
Catch-up vaccination:
• The maximum age for the first dose in the series is 14 
weeks, 6 days; vaccination should not be initiated for 
infants aged 15 weeks, 0 days, or older.
• The maximum age for the final dose in the series is 8 
months, 0 days.
• For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis 
(DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-
IPV [Kinrix, Quadracel]: 4 years)
Routine vaccination:
• Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 
15 through 18 months, and 4 through 6 years.  The fourth 
dose may be administered as early as age 12 months, 
provided at least 6 months have elapsed since the third 
dose.
• Inadvertent administration of fourth DTaP dose early:  
If the fourth dose of DTaP was administered at least 4 
months after the third dose of DTaP and the child was 12 
months of age or older, it does not need to be repeated.
Catch-up vaccination:
• The fifth dose of DTaP vaccine is not necessary if the 
fourth dose was administered at age 4 years or older.
• For other catch-up guidance, see Figure 2.
4. Haemophilus influenzae type b (Hib) conjugate vaccine.  
(Minimum age:  6 weeks for PRP-T [ActHIB, DTaP-IPV/Hib 
(Pentacel), Hiberix, and Hib-MenCY (MenHibrix)], PRP-
OMP [PedvaxHIB]) 
Routine vaccination:
• Administer a 2- or 3-dose Hib vaccine primary series 
and a booster dose (dose 3 or 4, depending on vaccine 
used in primary series) at age 12 through 15 months to 
complete a full Hib vaccine series.
• The primary series with ActHIB, MenHibrix, Hiberix, 
or Pentacel consists of 3 doses and should be 
administered at ages 2, 4, and 6 months. The primary 
series with PedvaxHIB consists of 2 doses and should be 
administered at ages 2 and 4 months; a dose at age 6 
months is not indicated.
• One booster dose (dose 3 or 4, depending on vaccine 
used in primary series) of any Hib vaccine should be 
administered at age 12 through 15 months. 
• For recommendations on the use of MenHibrix in patients 
at increased risk for meningococcal disease, refer to the 
meningococcal vaccine footnotes and also to MMWR 
February 28, 2014 / 63(RR01):1-13, available at www.cdc.
gov/mmwr/PDF/rr/rr6301.pdf.
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Y unger, UNITED STATES, 2017 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, s e the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the ACIP General 
Recommendations on Immunization and the relevant ACIP statement, available online at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
• Vaccine doses administered ≤4 days before the minimum interval are considered valid. Doses of any vaccine a ministered ≥5 days earlier than the minimum interval or minimum age should not 
be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see 
Table 1, Recommended and minimum ages and intervals between vaccine doses, in MMWR, General Recommendations on Immunization and Reports / Vol. 60 / No. 2, available online at www.cdc.gov/
mmwr/pdf/rr/rr6002.pdf.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, Vaccination of persons with primary and secondary immunodeficiencies, in General Recommendations 
on Immunization (ACIP), available at www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and Immunization in Special Clinical Circumstances, (American Academy of Pedatrics). In: Kimberlin DW, Brady MT, 
Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015:68-107.
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury p titions. Created by the National Childhood Vaccine 
Injury Act of 1986, it provides compensation to people found to be injured by certain vaccines. All vaccines within the recommended childhood immunization schedule are covered by VICP 
except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/index.html.
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
• Administer monovalent HepB vaccine to all newborns 
within 24 hours of birth.
• For infants born to hepatitis B surface antigen (HBsAg)-
positive mothers, administer HepB vaccine and 0.5 mL 
of hepatitis B immune globulin (HBIG) within 12 hours 
of birth. These infants should be tested for HBsAg and 
antibody to HBsAg (anti-HBs) at age 9 through 12 months 
(preferably at the next well-child visit) or 1 to 2 months 
after completion of the HepB series if the series was 
delayed.
• If mother’s HBsAg status is unknown, within 12 hours of 
birth, administer HepB vaccine regardless of birth weight. 
For infants weighing less than 2,000 grams, administer 
HBIG in addition to HepB vaccine within 12 hours of birth. 
Determine mother’s HBsAg status as soon as possible 
and, if mother is HBsAg-positive, also administer HBIG to 
infants weighing 2,000 grams or more as soon as possible, 
but no later than age 7 days.
Doses following the birth dose:
• The second dose should be administered at age 1 or 2 
months. Monovalent HepB vaccine should be used for 
doses administered before age 6 weeks.
• Infants who did not receive a birth dose should receive 3 
doses of a HepB-containing vaccine on a schedule of 0, 
1 to 2 months, and 6 months, starting as soon as feasible 
(see figure 2).
• Administer the second dose 1 to 2 months after the first 
dose (minimum interval of 4 weeks); administer the third 
dose at least 8 weeks after the second dose AND at least 
16 weeks after the first dose. The final (third or fourth) 
dose in the HepB vaccine series should be administered 
no earlier than age 24 weeks.
• Administration of a total of 4 doses of HepB vaccine is 
permitted when a combination vaccine containing HepB 
is administered after the birth dose. 
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose series.
• A 2-dose series (doses separated by at least 4 months) of 
adult formulation Recombivax HB is licensed for use in 
children aged 11 through 15 years. 
• For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both 
RV1 [Rotarix] and RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, administer a 2-dose series at ages 2 
and 4 months. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 
4, and 6 months. 
3. If any dose in the series was RotaTeq or vaccine product 
is unknown for any dose in the series, a total of 3 doses 
of RV vaccine should be administered. 
Catch-up vaccination:
• The maximum age for the first dose in the series is 14 
weeks, 6 days; vaccination should not be initiated for 
infants aged 15 weeks, 0 days, or older.
• The maximum age for the final dose in the series is 8 
months, 0 days.
• For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis 
(DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-
IPV [Kinrix, Quadracel]: 4 years)
Routine vaccination:
• Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 
15 through 18 months, and 4 through 6 years.  The fourth 
dose may be administered as early as age 12 months, 
provided at least 6 months have elapsed since the third 
dose.
• Inadvertent administration of fourth DTaP dose early:  
If the fourth dose of DTaP was administered at least 4 
months after the third dose of DTaP and the child was 12 
months of age or older, it does not need to be repeated.
Catch-up vaccination:
• The fifth dose of DTaP vaccine is not necessary if the 
fourth dose was administered at age 4 years or older.
• For other catch-up guidance, see Figure 2.
4. Haemophilus influenzae type b (Hib) conjugate vaccine.  
(Minimum age:  6 weeks for PRP-T [ActHIB, DTaP-IPV/Hib 
(Pentacel), Hiberix, and Hib-MenCY (MenHibrix)], PRP-
OMP [PedvaxHIB]) 
Routine vaccination:
• Administer a 2- or 3-dose Hib vaccine primary series 
and a booster dose (dose 3 or 4, depending on vaccine 
used in primary series) at age 12 through 15 months to 
complete a full Hib vaccine series.
• The primary series with ActHIB, MenHibrix, Hiberix, 
or Pentacel consists of 3 doses and should be 
administered at ages 2, 4, and 6 months. The primary 
series with PedvaxHIB consists of 2 doses and should be 
administered at ages 2 and 4 months; a dose at age 6 
months is not indicated.
• One booster dose (dose 3 or 4, depending on vaccine 
used in primary series) of any Hib vaccine should be 
administered at age 12 through 15 months. 
• For recommendations on the use of MenHibrix in patients 
at increased risk for meningococcal disease, refer to the 
meningococcal vaccine footnotes and also to MMWR 
February 28, 2014 / 63(RR01):1-13, available at www.cdc.
gov/mmwr/PDF/rr/rr6301.pdf.
Catch-up vaccination:
• If dose 1 was administered at ages 12 through 14 months, 
administer a second (final) dose at least 8 weeks after 
dose 1, regardless of Hib vaccine used in the primary 
series.
• If both doses were PRP-OMP (PedvaxHIB or COMVAX) and 
were administered before the first birthday, the third (and 
final) dose should be administered at age 12 through 59 
months and at least 8 weeks after the second dose.
• If the first dose was administered at age 7 through 11 
months, administer the second dose at least 4 weeks later 
and a third (and final) dose at age 12 through 15 months 
or 8 weeks after second dose, whichever is later.
• If first dose is administered before the first birthday and 
second dose administered at younger than 15 months, 
a third (and final) dose should be administered 8 weeks 
later.
• For unvaccinated children aged 15–59 months, 
administer only 1 dose.
• For other catch-up guidance, see Figure 2. For catch-up 
guidance related to MenHibrix, see the meningococcal 
vaccine footnotes and also MMWR February 28, 2014 / 
63(RR01):1-13, available at www.cdc.gov/mmwr/PDF/rr/
rr6301.pdf.
Vaccination of persons with high-risk conditions:
Children aged 12 through 59 months who are at increased 
risk for Hib disease, including chemotherapy recipients 
and those with anatomic or functional asplenia (including 
sickle cell disease), human  immunodeficiency virus (HIV ) 
infection, immunoglobulin deficiency, or early component 
complement  deficiency, who have received either no 
doses or only 1 dose of Hib vaccine before age 12 months, 
should receive 2 additional doses of Hib vaccine, 8 weeks 
apart; children who received 2 or more  doses of Hib vaccine 
before age 12 months should receive 1 additional dose.
• For patients younger than age 5 years undergoing 
chemotherapy or radiation treatment who received a 
Hib vaccine dose(s) within 14 days of starting therapy 
or during therapy, repeat the dose(s) at least 3 months 
following therapy completion.
• Recipients of hematopoietic stem cell transplant 
(HSCT) should be revaccinated with a 3-dose regimen 
of Hib vaccine starting 6 to 12 months after successful 
transplant, regardless of vaccination history; doses should 
be administered at least 4 weeks apart.
• A single dose of any Hib-containing vaccine should be 
administered to unimmunized* children and adolescents 
15 months of age and older undergoing an elective 
splenectomy; if possible, vaccine should be administered 
at least 14 days before procedure.
• Hib vaccine is not routinely recommended for patients 
5 years or older. However, 1 dose of Hib vaccine should 
be administered to unimmunized* persons aged 5 
years or older who have anatomic or functional asplenia 
(including sickle cell disease) and unimmunized* persons 
5 through 18 years of age with HIV infection.
* Patients who have not received a primary series and 
booster dose or at least 1 dose of Hib vaccine after 14 
months of age are considered unimmunized. 
5. Pneumococcal vaccines. (Minimum age: 6 weeks for 
PCV13, 2 years for PPSV23)
Routine vaccination with PCV13:
• Administer a 4-dose series of PCV13 at ages 2, 4, and 6 
months and at age 12 through 15 months.
Catch-up vaccination with PCV13:
• Administer 1 dose of PCV13 to all healthy children 
aged 24 through 59 months who are not completely 
vaccinated for their age.
• For other catch-up guidance, see Figure 2. 
Vaccination of persons with high-risk conditions with 
PCV13 and PPSV23:
• All recommended PCV13 doses should be administered 
prior to PPSV23 vaccination if possible.
• For children aged 2 through 5 years with any of the 
following conditions: chronic heart disease (particularly 
cyanotic congenital heart disease and cardiac failure); 
chronic lung disease (including asthma if treated with 
high-dose oral corticosteroid therapy); diabetes mellitus; 
cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic or 
functional asplenia; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; solid organ transplantation; or 
congenital immunodeficiency: 
1. Administer 1 dose of PCV13 if any incomplete schedule 
of 3 doses of PCV13 was received previously.
2. Administer 2 doses of PCV13 at least 8 weeks apart if 
unvaccinated or any incomplete schedule of fewer than 
3 doses of PCV13 was received previously.
3. The minimum interval between doses of PCV13 is 8 
weeks.
4. For children with no history of PPSV23 vaccination, 
administer PPSV23 at least 8 weeks after the most recent 
dose of PCV13.
• For children aged 6 through 18 years who have 
cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic 
or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previ-
ously, administer 1 dose of PCV13 now and 1 dose of 
PPSV23 at least 8 weeks later.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
2. If PCV13 has been received previously but PPSV23 has 
not, administer 1 dose of PPSV23 at least 8 weeks after 
the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, admin-
ister 1 dose of PCV13 at least 8 weeks after the most 
recent dose of PPSV23.
• For children aged 6 through 18 years with chronic heart 
disease (particularly cyanotic congenital heart disease 
and cardiac failure), chronic lung disease (including 
asthma if treated with high-dose oral corticosteroid 
therapy), diabetes mellitus, alcoholism, or chronic liver 
disease, who have not received PPSV23, administer 1 
dose of PPSV23. If PCV13 has been received previously, 
then PPSV23 should be administered at least 8 weeks 
after any prior PCV13 dose.
• A single revaccination with PPSV23 should be 
administered 5 years after the first dose to children 
with sickle cell disease or other hemoglobinopathies; 
anatomic or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma.
6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 
weeks)
Routine vaccination:
• Administer a 4-dose series of IPV at ages 2, 4, 6 through 
18 months, and 4 through 6 years. The final dose in the 
series should be administered on or after the fourth 
birthday and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months of life, minimum age and minimum 
intervals are only recommended if the person is at risk of 
imminent exposure to circulating poliovirus (i.e., travel to 
a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an 
additional dose should be administered at age 4 through 
6 years and at least 6 months after the previous dose.
• A fourth dose is not necessary if the third dose was 
administered at age 4 years or older and at least 6 months 
after the previous dose.
• If both oral polio vaccine (OPV) and IPV were 
administered as part of a series, a total of 4 doses should 
be administered, regardless of the child’s current age. 
If only OPV was administered, and all doses were given 
prior to age 4 years, 1 dose of IPV should be given at 4 
years or older, at least 4 weeks after the last OPV dose.
• IPV is not routinely recommended for U.S. residents aged 
18 years or older. 
• For other catch-up guidance, see Figure 2.
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2017
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the ACIP General Recommendations on Immunization and the relevant ACIP statement, avail-
able online at www.cdc.gov/v ccin s/hcp/acip-recs/index.html.
• For purposes of c lcula ing int rvals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
• Vaccine doses administered ≤4 days before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not be counted as valid doses and should be repeated as age-appropri-
ate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 1, Recommended and minimum ages and intervals between vaccine doses, in MMWR, General Recommendations on Immunization and 
Reports / Vol. 60 / No. 2, available online at www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with primary and seco dary immunodeficiencies, see Table 13, Vaccination of persons with primary and secondary immuno eficiencies, in General Recommendations on Immunization (ACIP), available at www.cdc.gov/mmwr/pdf/rr/rr6002.
pdf.; a d Immunization in Special Clinical Circumstances, (American Academy of P d trics). In: Ki berlin DW, Br dy MT, Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of 
Pediatrics, 2015:68-107.
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury petitions. Created by the National Childhood Vaccine Injury Act of 1986, it provides compensation to people found to be 
injured by certain vaccines. All vaccines within the recommended childhood immunization schedule are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/index.html.
Catch-up vaccination:
• If dose 1 was administered at ages 12 through 14 months, 
administer a second (final) dose at least 8 weeks after 
dose 1, regardless of Hib vaccine used in the primary 
series.
• If both doses were PRP-OMP (PedvaxHIB or COMVAX) and 
were administered before the first birthday, the third (and 
final) dose should be administered at age 12 through 59 
months and at least 8 weeks after the second dose.
• If the first dose was administered at age 7 through 11 
months, administer the second dose at least 4 weeks later 
and a third (and final) dose at age 12 through 15 months 
or 8 weeks after second dose, whichever is later.
• If first dose is administered before the first birthday and 
second dose administered at younger than 15 months, 
a third (and final) dose should be administered 8 weeks 
later.
• For unvaccinated children aged 15–59 months, 
administer only 1 dose.
• For other catch-up guidance, see Figure 2. For catch-up 
guidance relate  t  MenHibrix, see th  meningococcal
vaccine footnotes and also MMWR February 28, 2014 / 
63(RR01):1-13, available at www.cdc.gov/mmwr/PDF/rr/
rr6301.pdf.
Vaccination of persons with high-risk conditions:
Childre  aged 12 through 59 months who are at increased 
risk for Hib disease, including chemotherapy recipients 
and those with anatomic or functional asplenia (including 
sickle cell disease), human  immunodeficiency virus (HIV ) 
infection, immunoglobulin deficiency, or early component 
complement  deficiency, who have received either no 
doses or only 1 dose of Hib vaccine before age 12 months, 
should receive 2 additional doses of Hib vaccine, 8 weeks 
apart; children who received 2 or more  doses of Hib vaccine 
before age 12 months should receive 1 additional dose.
• For patients younger than age 5 years undergoing 
chemotherapy or radiation treatment who received a 
Hib vaccine dose(s) within 14 days of starting therapy 
or during therapy, repeat the dose(s) at least 3 months 
following therapy completion.
• Recipients of hemato oieti  stem cell transplant 
(HSCT) sh uld be revaccinated with a 3-dose regimen 
of Hib vaccine starting 6 to 12 months after successful 
transplant, regardless of vaccination history; doses should 
be administered at least 4 weeks apart.
• A single dose of any Hib-containing vaccine should be 
administered to unimmunized* children and adolescents 
15 months of age and older undergoing an elective 
splenectomy; if possible, vaccine should be administered 
at least 14 days before procedure.
• Hib vaccine is not routinely recommended for patients 
5 years or older. However, 1 dose of Hib vaccine should 
be administered to unimmunized* persons aged 5 
years or older who have anatomic or functional asplenia 
(including sickle cell disease) and unimmunized* persons 
5 through 18 years of age with HIV infection.
* Patients who have not received a primary series and 
booster dose or at least 1 dose of Hib vaccine after 14 
months of age are considered unimmunized. 
5. Pneumococcal vaccines. (Minimum age: 6 weeks for 
PCV13, 2 years for PPSV23)
Routine vaccination with PCV13:
• Administer a 4-dose series of PCV13 at ages 2, 4, and 6 
months and at age 12 through 15 months.
Catch-up vaccination with PCV13:
• Administer 1 dose of PCV13 to all healthy children 
aged 24 through 59 months who are not completely 
vaccinated for their age.
• For other catch-up guidance, see Figure 2. 
Vaccination of persons with high-risk conditions with 
PCV13 and PPSV23:
• All recommended PCV13 doses should be administered 
prior to PPSV23 vaccination if possible.
• For children aged 2 through 5 years with any of the 
following conditions: chronic heart disease (particularly 
cyanotic congenital heart disease and cardiac failure); 
chronic lung disease (including asthma if treated with 
high-dose oral corticosteroid therapy); diabetes mellitus; 
cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic or 
functional asplenia; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplas s, leukemias, lymphomas, 
and Hodgkin disease; solid organ transplantation; or 
congenital immunodeficiency: 
1. Administer 1 dose of PCV13 if any incomplete schedule 
of 3 doses of PCV13 was received previously.
2. Admi ister 2 doses of PCV13 at least 8 weeks apart if 
unvaccinated or any incomplete schedule f fewer than 
3 doses of PCV13 was received previously.
3. The minimum interval between doses of PCV13 is 8 
we ks.
4. For children with no history of PPSV23 vaccination, 
administer PPSV23 at least 8 weeks after the most recent 
dose of PCV13.
• For children aged 6 through 18 years who have 
ce ebrospinal fluid leak; cochlear implant; sickle cell 
dise se and other hemoglobinopathies; anatomic 
or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previ-
ously, administer 1 dose of PCV13 now and 1 dose of 
PPSV23 at least 8 weeks later.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
2. If PCV13 has been received previously but PPSV23 has 
not, administer 1 dose of PPSV23 at least 8 weeks after 
the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, admin-
ister 1 dose of PCV13 at least 8 weeks after the most 
recent dose of PPSV23.
• For children aged 6 through 18 years with chronic heart 
disease (particularly cyanotic congenital heart disease 
and cardiac failure), chronic lung disease (including 
asthma if treated with high-dose oral corticosteroid 
therapy), diabetes mellitus, alcoholism, or chronic liver 
disease, who have not received PPSV23, administer 1 
dose of PPSV23. If PCV13 has been received previously, 
then PPSV23 should be administered at least 8 weeks 
after any prior PCV13 dose.
• A single revaccination with PPSV23 should be 
administered 5 years after the first dose to children 
with sickle cell disease or other hemoglobinopathies; 
anatomic or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple yeloma.
6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 
weeks)
Routine vaccination:
• Administer a 4-dose series of IPV at ages 2, 4, 6 through 
18 months, and 4 through 6 years. The final dose in the 
series should be administered on or after the fourth 
birthday and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months of life, minimum age and minimum 
intervals are only recommended if the person is at risk of 
imminent exposure to circulating poliovirus (i.e., travel to 
a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an 
additional dose should be administered at age 4 through 
6 years and at least 6 months after the previous dose.
• A fourth dose is not necessary if the third dose was 
administered at age 4 years or older and at least 6 months 
after the previous dose.
• If both oral polio vaccine (OPV) and IPV were 
administered as part of a series, a total of 4 doses should 
be administered, regardless of the child’s current age. 
If only OPV was administered, and all doses were given 
prior to age 4 years, 1 dose of IPV should be given at 4 
years or older, at least 4 weeks after the last OPV dose.
• IPV is not routinely recommended for U.S. residents aged 
18 years or older. 
• For other catch-up guidance, see Figure 2.
Catch-up vaccination:
• If do e 1 was administere  at ages 12 through 14 months, 
administer a second (final) dose at least 8 weeks after 
dose 1, regardle s f Hib vaccine used in the primary 
series.
• If both doses were PRP-OMP (PedvaxHIB or COMVAX) and 
were dministered before the first birthday, the third (and 
final)  should be administered at age 12 through 59 
months and at least 8 weeks after the second dose.
• If th  first dose was administered at age 7 through 11 
months, administer the second dose at least 4 weeks later 
and a third (and final) d se at age 12 through 15 months 
or 8 weeks after second dose, whichever is later.
• If first do e is administered before th  first birthday and 
second dose administered at younger than 15 months, 
a third (and final) dose should be administered 8 weeks 
later.
• For unvaccinated children aged 15–59 months, 
admini ter only 1 dose.
• For oth r catc -up guidance, se  Figure 2. For catch-up 
guidanc  related to MenHibrix, see the meningococcal 
vaccine footnotes and also MMWR February 28, 2014 / 
63(RR01):1-13, available at www.cdc.gov/mmwr/PDF/rr/
rr6301.pdf.
Vaccination of persons with high-risk conditions:
Children aged 12 through 59 months who are at increased 
risk for Hib disease, including chemotherapy recipients 
and those with anatomic or functional asplenia (including 
sickle cell disease), human  immunodeficiency virus (HIV ) 
infection, immunoglobulin deficiency, or early component 
complement  deficiency, who have received either no 
doses or only 1 dose of Hib vaccine before age 12 months, 
should receive 2 additional doses of Hib vaccine, 8 weeks 
apart; children who received 2 or more  doses of Hib vaccine 
before age 12 months should receive 1 additional dose.
• For patients younger than age 5 years undergoing 
chemotherapy or radiation treatment who received a 
Hib vaccine dose(s) within 14 days of starting therapy 
or during therapy, repeat the dose(s) at least 3 months 
following therapy completion.
• Recipients of hematopoietic stem cell transplant 
(HSCT) should be revacci ated with a 3-dose regimen 
of Hib vaccine starting 6 to 12 months after successful 
transplant, regardless of vaccination history; doses should 
be administered at least 4 weeks apart.
• A singl  dose f any Hib-containing vaccine should be 
administer d to unimmunize * children and adolescents 
15 months of age and older undergoing an elective 
splenectomy; if possible, vaccine should be administered 
at least 14 days before procedure.
• Hib vaccine is not routinely recommended for patients 
5 years or older. However, 1 dose of Hib vaccine should 
be administered to unimmunized* persons aged 5 
years or older wh  have anatomic or functional asplenia 
(including sickle cell disease) and unimmunized* persons 
5 through 18 years of age with HIV infection.
* Patients who have not received a primary series and 
booster dose or at least 1 dose of Hib vaccine after 14 
months of age are considered unimmunized. 
5. Pneumococcal vaccines. (Minimum age: 6 weeks for 
PCV13, 2 years for PPSV23)
Routine vaccination with PCV13:
• Administer a 4-dose series of PCV13 at ages 2, 4, and 6 
months and at age 12 through 15 months.
Catch-up vaccination with PCV13:
• Administer 1 dose of PCV13 to all healthy children 
aged 24 through 59 months who are not completely 
vaccinat d for thei  age.
• For ther catch-up g idance, see Figure 2. 
Vaccination of p rsons with high-risk conditions with 
PCV13 and PPSV23:
• All recommended PCV13 doses should be administered 
prior to PPSV23 cci ation if possible.
• For children aged 2 through 5 years with any of the 
following conditions: chronic heart disease (particularly 
cyanotic congenital heart disease and cardiac failure); 
chronic lung disease (including asthma if treated with 
high-dose oral corticosteroid therapy); diabetes mellitus; 
cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic or 
functional asplenia; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin dis ase; solid organ transplantation; or 
conge ital immunodeficiency: 
1. Administer 1 dose of PCV13 if any incomplete schedule 
of 3 doses of PCV13 was received previously.
2. Administer 2 doses of PCV13 at least 8 weeks apart if 
unvaccinated or any incomplete schedule of fewer than 
3 doses of PCV13 was received previously.
3. The minimum interval between doses of PCV13 is 8 
weeks.
4. For children with no history of PPSV23 vaccination, 
administer PPSV23 at least 8 weeks after the most recent 
dose of PCV13.
• For children aged 6 through 18 years who have 
cerebr spin l fluid leak; cochlear implant; sickle cell 
disease and other emoglobinopathies; anatomic 
or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previ-
ously, administer 1 dose of PCV13 now and 1 dose of 
PPSV23 at least 8 weeks later.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
2. If PCV13 has been received previously but PPSV23 has 
not, administer 1 dose of PPSV23 at least 8 weeks after 
the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, admin-
ister 1 dose of PCV13 at least 8 weeks after the most 
recent dose of PPSV23.
• For children aged 6 through 18 years with chronic heart 
disease (particularly cyanotic congenital heart disease 
and cardiac failure), chronic lung disease (including 
asthma if treated with high-d se oral corticosteroid 
ther py), diabe e  mellitus, alcoholism, or chronic liver 
disease, who have not received PPSV23, administer 1 
of PPSV23. If PCV13 has been received previously, 
then PPSV23 should be administered at least 8 weeks 
after any prior PCV13 dose.
• A ingle r vaccinatio  with PPSV23 should be 
administered 5 years afte  the first dose to children 
with sickle cell disease or other hemoglobinopathies; 
anatomic or functional asplenia; congenital or acquired 
immuno eficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma.
6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 
weeks)
Routine vaccination:
• Administer a 4-dose series of IPV at ages 2, 4, 6 through 
18 months, and 4 through 6 years. The final dose in the 
series should be administered on or after the fourth 
birthday and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months of life, minimum age and minimum 
intervals are only recommended if the person is at risk of 
imminent exposure to circulating poliovirus (i.e., travel to 
a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an 
additional dose should be administered at age 4 through 
6 years and at least 6 months after the previous dose.
• A fourth dose is not necessary if the third dose was 
administered at age 4 years or older and at least 6 months 
after the previous dose.
• If both oral polio vaccine (OPV) and IPV were 
administered as part of a series, a total of 4 doses should 
be administered, regardless of the child’s current age. 
If only OPV was administered, and all doses were given 
prior to age 4 years, 1 dose of IPV should be given at 4 
years or older, at least 4 weeks after the last OPV dose.
• IPV is not routinely recommended for U.S. residents aged 
18 years or older. 
• For other catch-up guidance, see Figure 2.
Catch-up vaccination:
• If dose 1 was administered at ages 12 through 14 months, 
administer a s c nd (final) dose at least 8 weeks after 
dose 1, regardless of Hib vaccine used in the primary 
seri s.
• If both doses were PRP-OMP (PedvaxHIB or COMVAX) and 
were administered before th first birthday, the third (and 
final) dose should b  dministered at age 12 through 59 
m nths and at least 8 weeks aft r the second dose.
• If the first dose was administered at age 7 through 11 
months, administer the second dose at least 4 weeks later 
and a third (and final) dose at age 12 through 15 months 
or 8 weeks after second dose, whichever is later.
• If first dose is administered before the first birthday and 
second dose administered at younger than 15 months, 
a third (and final) dose should be administered 8 weeks 
later.
• For unvaccinated children aged 15–59 months, 
administer only 1 dose.
• For other catch-up guidance, see Figure 2. For catch-up 
guidance related to MenHibrix, see the meningococcal 
vaccine footnotes and also MMWR February 28, 2014 / 
63(RR01):1-13, available at www.cdc.gov/mmwr/PDF/rr/
rr6301.pdf.
Vaccination of persons with high-risk conditions:
Children aged 12 through 59 months who are at incr ased 
risk for Hib disease, including chemotherapy recipients 
and those with anatomic or functional asplenia (includi g 
sickle cell disease), human  immunodeficiency virus (HIV ) 
infection, immunoglobulin deficiency, or early component 
complement  deficiency, who have received either no 
doses or only 1 dose of Hib vaccine before age 12 months, 
should receive 2 additional doses of Hib vaccine, 8 weeks 
apart; children who received 2 or more  doses of Hib vaccine 
before age 12 months should receive 1 additional dose.
• For patients younger than age 5 years undergoing 
chemotherapy or radiation treatment who received a 
Hib vaccine dose(s) within 14 days of starting therapy 
or during therapy, repeat the dose(s) at least 3 months 
following therapy completion.
• Recipients of hematopoietic stem cell transplant 
(HSCT) should be revaccinated with a 3-dose regimen 
of Hib vaccine starting 6 to 12 months after successful 
transplant, regardless of vaccination history; doses should 
be administered at least 4 weeks apart.
• A single dose of any Hib-containing vaccine should be 
administered to unimmunized* children and adolescents 
15 months of age and older undergoing an elective 
splenectomy; if possible, vaccine should be administered 
at least 14 days before procedure.
• Hib vaccine is not routinely recommended for patients 
5 years or older. However, 1 dose of Hib vaccine should 
be administered to unimmunized* persons aged 5 
years or older who have anatomic or functional asplenia 
(including sickle cell disease) and nimmunized* persons 
5 through 18 ye rs of age with HIV infection.
* Pa ients who hav  not receiv d a primary series and 
booster dose or at least 1 dose of Hib vaccine after 14 
months of age are considered unimmunized. 
5. Pneumococcal vaccines. (Minimum age: 6 weeks for 
PCV13, 2 years for PPSV23)
Routine vaccination with PCV13:
• Administer a 4-dose series of PCV13 at ages 2, 4, and 6 
months and at age 12 through 15 months.
Catch-up vaccination with PCV13:
• Administer 1 dose of PCV13 to all healthy children 
aged 24 through 59 months who are not completely 
vaccinated for their age.
• For other catch-up guidance, see Figure 2. 
Vaccination of persons with high-risk conditions with 
PCV13 and PPSV23:
• All recommended PCV13 doses should be administered 
pri r to PPSV23 vaccination if possible.
• For children ag d 2 through 5 years with any of the 
following conditions: chronic heart disease (particularly 
cyanotic congenital heart disease and cardiac failure); 
chronic lung disease (including asthma if treated with 
high-dose oral corticosteroid therapy); diabetes mellitus; 
cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic or 
functional asplenia; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; solid organ transplantation; or 
congenital immun deficiency: 
1. Administ r 1 dose of PCV13 if any incomplete schedule 
of 3 doses of PCV13 was received previously.
2. Admi ist r 2 oses of PCV13 at least 8 weeks apart if 
unvaccinated or ny incomplete schedule of fewer than 
3 doses of PCV13 was re eived previously.
3. The minimum interval between doses of PCV13 is 8 
weeks.
4. For children with no history of PPSV23 vaccination, 
administer PPSV23 at least 8 weeks after the most recent 
dose of PCV13.
• For children aged 6 through 18 years who have 
cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic 
or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previ-
ously, administer 1 dose of PCV13 now and 1 dose of 
PPSV23 at least 8 weeks later.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/i dex.html.
2. If PCV13 has been received previously but PPSV23 has 
not, administer 1 dose of PPSV23 at least 8 weeks after 
the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, admin-
ister 1 dose of PCV13 at least 8 weeks after the most 
recent dose of PPSV23.
• For children aged 6 through 18 years with chronic heart 
disease (particularly cyanotic congenital heart disease 
and cardiac failure), chronic lung disease (including 
asthma if treated with high-dose oral corticosteroid 
therapy), diabetes mellitus, alcoholism, or chronic liver 
disease, who have not received PPSV23, administer 1 
dose of PPSV23. If PCV13 has been received previously, 
then PPSV23 should be administered at least 8 weeks 
after any prior PCV13 dose.
• A single revaccination with PPSV23 should be 
administered 5 years after the first dose to children 
with sickle cell disease or other hemoglobinopathies; 
anatomic or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment 
with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin disease; generalized malignancy; solid 
organ transplantation; or multiple myeloma.
6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 
weeks)
Routine vaccination:
• Administer a 4-dose series of IPV at ages 2, 4, 6 through 
18 months, and 4 through 6 years. The final dose in the 
series should be administered on or after the fourth 
birthday and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months of life, minimum age and minimum 
intervals are only recommended if the person is at risk of 
imminent exposure to circulating poliovirus (i.e., travel to 
a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an 
additional dose should be administered at age 4 through 
6 years and at least 6 months after the previous dose.
• A fourth dose is not necessary if the third dose was 
administered at age 4 years or older and at least 6 months 
after the previous dose.
• If both oral polio vaccine (OPV) and IPV were 
administered as part of a series, a total of 4 doses should 
be administered, regardless of the child’s current age. 
I  only OPV was administered, and all doses were given 
pri r to age 4 years, 1 d se of IPV should be given at 4 
years or older, at least 4 weeks after the last OPV dose.
• IPV is ot routinely recommended for U.S. residents aged 
18 years or older. 
• For other catch-up guidance, see Figure 2.For further guidance on the use of the vaccines m ntioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
7. Influenza vaccines. (Minimu  age: 6 months for inacti-
vated influenza vaccine [IIV], 18 years for recombinant 
influenza vaccine [RIV]) 
Routine vaccination:
• Administer influenza vaccine annually to all children 
beginning at age 6 months. For the 2016–17 season, 
use of live attenuated influenza vaccine (LAIV) is not 
recommended.
For children aged 6 months through 8 years:
• For the 2016–17 season, administer 2 doses (separated by 
at least 4 weeks) to children who are receiving influenza 
vaccine for the first time or who have not previously 
received ≥2 doses of trivalent or quadrivalent influenza 
vaccine before July 1, 2016. For additional guidance, 
follow dosing guidelines in the 2016–17 ACIP influenza 
vaccine recommendations (see MMWR August 26, 
2016;65(5):1-54, available at  
www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf).
• For the 2017–18 season, follow dosing guidelines i  the 
2017–18 ACIP influenza vaccine recommendations.  
For persons aged 9 years and older:
• Administer 1 d se.
8. Measles, mumps, and rubella (MMR) vaccine. (Minimum 
age: 12 months for routine vaccination)
Routine vaccination:
• Administer a 2-dose series of MMR vaccine at ages 12 
throu h 15 months and 4 through 6 years. The second 
dose may be dminister  before age 4 years, provided at 
least 4 weeks have elapsed since the first dose.
• Administer 1 dose of MMR vaccine to infants aged 6 
through 11 months before departure from the United 
States for international travel. These children should be 
revaccinated with 2 doses of MMR vaccine, the first at age 
12 through 15 months (12 months if the child remains in 
an area where disease risk is high), and the second dose at 
least 4 weeks later.
• Administer 2 doses of MMR vaccine to children aged 
12 months and older before departure from the United 
States for international travel. The first dose should be 
administered on or after age 12 months and the second 
dose at least 4 weeks later.
Catch-up vaccination:
• Ensure that all school-aged children and adolescents 
have had 2 doses of MMR vaccine; the minimum interval 
between the 2 doses is 4 weeks.  
9. Varicella (VAR) vaccine. (Minimum age: 12 months) 
Routine vaccination:
• Administer a 2-dose series of VAR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered before age 4 years, provided 
at least 3 months have elapsed since the first dose. If the 
second dose was administered at least 4 weeks after the 
first dose, it can be accepted as valid.
Catch-up vaccination:
• Ensure that all persons aged 7 through 18 years without 
evidence of immunity (see MMWR 2007;56[No. RR-4], 
available at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf ) have 
2 doses of varicella vaccine.  For children aged 7 through 
12 years, the recommended minimum interval between 
doses is 3 months (if the second dose was administered 
at least 4 weeks after the first dose, it can be accepted as 
valid); for persons aged 13 years and older, the minimum 
interval between doses is 4 weeks.
10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Routine vaccination:
• Initiate the 2-dose HepA vaccine series at ages 12 through 
23 months; separate the 2 doses by 6 to 18 months.
• Childr n who have r ceived 1 dose of HepA vaccine 
before age 24 months should receive a second dose 6 to 
18 months after the first dose.
• For any person aged 2 years a d older who has not 
already rec ived the HepA vaccine series, 2 doses of 
HepA vacci e separated by 6 to 18 months may be 
administered if immunity against hepatitis A virus 
infection is desired. 
Catch-up vaccination:
• The minimum interval between the 2 doses is 6 months. 
Special populations: 
• Administer 2 doses of HepA vaccine at least 6 months apart 
to previously unvaccinated persons who live in areas where 
vaccination programs target older children, or who are at 
increased risk for infection.  This includes persons traveling 
to or working in countries that have high or intermediate 
endemicity of infection; men having sex with men; users 
of injection and non-injection illicit drugs; persons who 
work with HAV-infected primates or with HAV in a research 
laboratory; persons with clotting-factor disorders; persons 
with chronic liver disease; and persons who anticipate 
close, personal contact (e.g., household or regular 
babysitting) with an international adoptee during the first 
60 days after arrival in the United States from a country 
with high or intermediate endemicity. The first dose should 
be administered as soon as the adoption is planned, ideally, 
2 or more weeks before the arrival of the adoptee.
11. Meningococcal vaccines. (Minimum age: 6 weeks for 
Hib-MenCY [MenHibrix], 2 months for MenACWY-CRM 
[Menveo], 9 months for MenACWY-D [Menactra], 10 years 
for serogroup B meningococcal [MenB] vaccines: MenB-
4C [Bexsero] and MenB-FHbp [Trumenba])
Routine vaccination:
• Administer a single dose of Menactra or Menveo vaccine 
at age 11 through 12 years, with a booster dose at age 16 
years.
• For children aged 2 months through 18 years with high-
risk conditions, see “Meningococcal conjugate ACWY 
vaccination of persons with high-risk conditions and 
other persons at increased risk” and “Meningococcal B 
vaccination of persons with high-risk conditions and other 
persons at increased risk of disease” below.
Catch-up vaccination:
• Administer Menactra or Menveo vaccine at age 13 through 
18 years if not previously vaccinated.
• If the first dose is administered at age 13 through 15 years, 
a booster dose should be administered at age 16 through 
18 years, with a minimum interval of at least 8 weeks 
between doses.
• If the first dose is administered at age 16 years or older, a 
booster dose is not needed.
• For other catch-up guidance, see Figure 2.
Clinical discretion:
• Young adults aged 16 through 23 years (preferred age 
range is 16 through 18 years) who are not at increased 
risk for meningococcal disease may be vaccinated with a 
2-dose series of either Bexsero (0, ≥1 month) or Trumenba 
(0, 6 months) vaccine to provide short-term protection 
against most strains of serogroup B meningococcal 
disease. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
• If the second dose of Trumenba is given at an interval of 
<6 months, a third dose should be given at least 6 months 
after the first dose; the minimum interval between the 
second and third doses is 4 weeks.
Meningococcal conjugate ACWY vaccination of persons 
with high-risk conditions and other persons at increased 
risk: 
Children with anatomic or functional asplenia (including 
sickle cell disease), children with HIV infection, or children 
with persistent complement component deficiency 
(includes persons with inherited or chronic deficiencies 
in C3, C5-9, properdin, factor D, factor H, or taking 
eculizumab [Soliris]):
 ▪ Menveo  
 ɱ Children who initiate vaccination at 8 weeks. Administer 
doses at ages 2, 4, 6, and 12 months.
 ɱ Unvaccinated children who initiate vaccination at 7 
through 23 months. Administer 2 primary doses, with 
the second dose at least 12 weeks after the first dose 
AND after the first birthday.
 ɱ Children 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 8 
weeks apart.
 ▪ MenHibrix
 ɱ Children who initiate vaccination at 6 weeks. Administer 
doses at ages 2, 4, 6, and 12 through 15 months.
 ɱ If the first dose of MenHibrix is given at or after age 12 
months, a total of 2 doses should be given at least 8 
weeks apart to ensure protection against serogroups 
C and Y meningococcal disease.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
7. Influenza vaccines. (Minimum age: 6 months for inacti-
vated i fluenza vaccine [IIV], 18 years for recombinant 
influenza vaccine [RIV]) 
Rout ne vaccination:
• Administer influenza vacci e annually to all children 
beginning at age 6 months. For the 2016–17 season, 
use of live attenuated influenza vaccine (LAIV) is not 
recommended.
For children aged 6 months through 8 years:
• For the 2016–17 season, administer 2 doses (separated by 
at least 4 weeks) to children who are receiving influenza 
vaccine for the first time or who have not previously 
received ≥2 doses of trivalent or quadrivalent influenza 
vaccine before July 1, 2016. For additional guidance, 
follow dosing guidelines i  the 2016–17 ACIP i fluenza 
vaccine recommendations (see MMWR August 26, 
2016;65(5):1-54, available at  
www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf).
• For the 2017–18 season, follow dosing guidelines in the 
2017–18 ACIP influenza vaccine recommendations.  
For persons aged 9 years and older:
• Administer 1 dose.
8. Measles, mumps, and rubella (MMR) vaccine. (Minimum 
age: 12 months for routine vaccination)
Routine vaccination:
• Administer a 2-dose series of MMR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered before age 4 years, provided at 
least 4 weeks have elapsed since the first dose.
• A minister 1 dose of MMR vaccine to infants aged  
through 1  months before departure from the United 
St tes for international travel. These children should be 
r vaccinated wi  2 doses f MMR vaccine, the first at age 
12 through 15 months (12 months if the child remains in 
an area where disease risk is high), and the second dose at 
l ast 4 w eks later.
• Administer 2 doses of MMR vaccine to children aged 
12 months and older before departure from the United 
States for international travel. The first dose should be 
administered on or after age 12 months and the second 
dose at least 4 weeks later.
Catch-up vaccination:
• Ensure that all school-aged children and adolescents 
have had 2 doses of MMR vaccine; the minimum interval 
between the 2 doses is 4 weeks.  
9. Varicella (VAR) vaccine. (Minimum age: 12 months) 
Routine vaccination:
• Administer a 2-dose series of VAR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered befor  age 4 years, provided 
at least 3 m ths have lapsed since the first dose. If the 
second dose wa  administered at least 4 weeks after the 
first dose, it can be accepted as valid.
Catch-up vaccination:
• Ensure that all persons aged 7 through 18 years without 
evidence of immunity (see MMWR 2007;56[No. RR-4], 
available at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf ) have 
2 doses of varicella vaccine.  For children aged 7 through 
12 years, the recommended minimum interval between 
doses is 3 months (if the second dose was administered 
at least 4 weeks after the first dose, it can be accepted as 
valid); for persons aged 13 years and older, the minimum 
interval between doses is 4 weeks.
10. Hepatitis A (HepA) v ccine. (Minimum age: 12 months)
Routine vaccination:
• Initiate the 2-dose HepA vaccine series at ages 12 through 
23 months; separ te the 2 doses by 6 to 18 months.
• Child en who have received 1 dose of HepA vaccine 
before age 24 months should receive a second dose 6 to 
18 months after the first dose.
• For any person aged 2 years and older who has not 
alr ady received th  HepA vaccine series, 2 doses of 
HepA vaccine separated by 6 t  18 months may be 
administered if immunity against hepatitis A virus 
infection is desired. 
Catch-up vaccination:
• The minimum interval between the 2 doses is 6 months. 
Special populations: 
• Administer 2 doses of HepA vaccine at least 6 months apart 
to previously unvaccinated persons who live in areas where 
vaccination programs target older children, or who are at 
increased risk for infection.  This includes persons traveling 
to or working in countries that have high or intermediate 
endemicity of infection; men having sex with men; users 
of injection and non-injection illicit drugs; persons who 
work with HAV-infected primates or with HAV in a research 
laboratory; persons with clotting-factor disorders; persons 
with chronic liver disease; and persons who anticipate 
close, personal contact (e.g., household or regular 
babysitting) with an international adoptee during the first 
60 days after arrival in the United States from a country 
with high or intermediate endemicity. The first dose should 
be administered as soon as the adoption is planned, ideally, 
2 or ore weeks before the arrival of the adoptee.
11. Meningococcal vaccines. (Minimum age: 6 weeks for 
Hib-Me CY [MenHibrix], 2 months for MenACWY-CRM 
[Menveo], 9 months for MenACWY-D [Menactra], 10 years 
for serogroup B meningococcal [MenB] vaccines: MenB-
4C [Bexsero] and MenB-FHbp [Trumenba])
Routine vaccination:
• Administer a single dose of Menactra or Menveo vaccine 
at age 11 through 12 years, with a booster dose at age 16 
years.
• For children aged 2 months through 18 years with high-
risk conditions, see “Meningococcal conjugate ACWY 
vaccination of persons with high-risk conditions and 
other persons at increased risk” and “Meningococcal B 
vaccination of persons with high-risk conditions and other 
persons at increased risk of disease” below.
Catch-up vaccination:
• Administer Menactra or Menveo vaccine at age 13 through 
18 years if not previously vaccinated.
• If the first dose is administered at age 13 through 15 years, 
a booster dose should be administered at age 16 through 
18 years, with a minimum interval of at least 8 weeks 
between doses.
• If the first dose is administered at age 16 years or older, a 
booster dose is not needed.
• For other catch-up guidance, see Figure 2.
Clinical discretion:
• Young adults aged 16 through 23 years (preferred age 
range is 16 through 18 years) who are not at increased 
risk for meningococcal disease may be vaccinated with a 
2-dose series of either Bexsero (0, ≥1 month) or Trumenba 
(0, 6 months) vaccine to provide short-term protection 
against most strains of serogroup B meningococcal 
disease. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
• If the second dose of Trumenba is given at an interval of 
<6 months, a third dose should be given at least 6 months 
after the first dose; the minimum interval between the 
second and third doses is 4 weeks.
Meningococcal conjugate ACWY vaccination of persons 
with high-risk conditions and other persons at increased 
risk: 
Children with anatomic or functional asplenia (including 
sickle cell disease), children with HIV infection, or children 
with persistent complement component deficiency 
(includes persons with inherited or chronic deficiencies 
in C3, C5-9, properdin, factor D, factor H, or taking 
eculizumab [Soliris]):
 ▪ Menveo  
 ɱ Children who initiate vaccination at 8 weeks. Administer 
doses at ages 2, 4, 6, and 12 months.
 ɱ Unvaccinated children who initiate vaccination at 7 
through 23 months. Administer 2 primary doses, with 
the second dose at least 12 weeks after the first dose 
AND after the first birthday.
 ɱ Children 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 8 
weeks apart.
 ▪ MenHibrix
 ɱ Children who initiate vaccination at 6 weeks. Administer 
doses at ages 2, 4, 6, and 12 through 15 months.
 ɱ If the first dose of MenHibrix is given at or after age 12 
months, a total of 2 doses should be given at least 8 
weeks apart to ensure protection against serogroups 
C and Y meningococcal disease.For furthe  guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
7. Influ nza vaccin s. (Minimum age: 6 months for inacti-
vated influenza vaccine [IIV], 18 years for recombinant 
influenza vaccine [RIV]) 
Routine vaccination:
• Ad i ister i fluenza vaccine annually to all children 
beginning at age 6 months. For the 2016–17 season, 
use of live attenuated influenza vaccine (LAIV) is not 
recommended.
For children aged 6 months through 8 years:
• For the 2016–17 season, administer 2 doses (separated by 
at least 4 weeks) to children who are receiving influenza 
vaccine for the first time or who have not previously 
received ≥2 doses of trivalent or quadrivalent influenza 
vaccine before July 1, 2016. For additional guidance, 
follow dosing guidelines in the 2016–17 ACIP influenza 
vaccine rec mmendations (see MMWR August 26, 
2016;65(5):1-54, available at  
www.c c.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf).
• For the 2017–18 s ason, follow dosing guidelines in the 
2017–18 ACIP influenza v cci e recommendations.  
For perso s aged 9 years and older:
• Administer 1 dose.
8. Measles, mumps, and ubella (MMR) vaccine. (Minimum 
age: 12 months for routine vaccination)
R utine vaccination:
• Administer a 2-dose series of MMR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered before age 4 years, provided at 
least 4 weeks have elapsed since the first dose.
• Administer 1 dose of MMR vaccine to infants aged 6 
through 11 months before departure from the United 
States for international travel. These children should be 
revaccinated with 2 doses of MMR vaccine, the first at age 
12 through 15 months (12 months if the child remains in 
an area where disease risk is high), and the second dose at 
least 4 weeks later.
• Administer 2 doses of MMR vaccine to children aged 
12 months and older before departure from the United 
States for international travel. The first dose should be 
administered on or after age 12 months and the second 
dose at least 4 weeks later.
Catch-up vaccination:
• Ensure that all school-aged children and adolescents 
h ve had 2 doses f MMR vaccine; t e minimum interval 
betwe n the 2 doses is 4 weeks.  
9. Varicella (VAR) vaccine. (Minimum age: 12 months) 
Routin  vaccination:
• Administer a 2-dose series of VAR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered before age 4 years, provided 
at least 3 months have elapsed since the first dose. If the 
second dose was administered at least 4 weeks after the 
first dose, it can be accepted as valid.
Catch-up v cination:
• Ensure that all persons aged 7 through 18 years without 
evidence of immunity (see MMWR 2007;56[No. RR-4], 
available at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf ) have 
2 doses of varicella vaccine.  For children aged 7 through 
12 years, the recommended minimum interval between 
doses is 3 months (if the second dose was administered 
at least 4 weeks after the first dose, it can be accepted as 
valid); for persons aged 13 years and older, the minimum 
interval between doses is 4 weeks.
10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Routine vaccination:
• Initiate the 2-dose HepA vaccine series at ages 12 through 
23 months; separate the 2 doses by 6 to 18 months.
• Children who have received 1 dose of HepA vaccine 
before age 24 months should receive a second dose 6 to 
18 months after the first dose.
• For any person aged 2 years and older who has not 
already received the HepA vaccine series, 2 doses of 
HepA vaccine separated by 6 to 18 months may be 
administered if immunity against hepatitis A virus 
infection is desired. 
Catch-up vaccination:
• The minimum interval between the 2 doses is 6 months. 
Special populations: 
• Ad inister 2 doses of HepA vaccine at least 6 months apart 
to previously unvaccinated persons who live in areas where 
vaccination programs target older children, or who are at 
increased risk for infection.  This includes persons traveling 
to or working in countries that have high or intermediate 
endemicity of infection; men having sex with men; users 
of inj ction and non-injection illicit drugs; persons who 
work with HAV-infected primates r with HAV in a research 
laboratory; persons with clotting-factor disorders; persons 
with chronic liver disease; and persons who anticipate 
close, p rson l contact (e.g., household or regular 
babysitting) with an international adoptee during the first 
60 days after arrival in the United States from a country 
with high or intermediate endemicity. The first dose should 
be administered as soon as the adoption is planned, ideally, 
2 or more weeks before the arrival of the adoptee.
11. Meningococcal vaccines. (Minimum age: 6 weeks for 
Hib-MenCY [MenHibrix], 2 months for MenACWY-CRM 
[Menveo], 9 months for MenACWY-D [Menactra], 10 years 
for serogroup B meningococcal [MenB] vaccines: MenB-
4C [Bexsero] and MenB-FHbp [Trumenba])
Routine vaccination:
• Administer a single dose of Menactra or Menveo vaccine 
at age 11 through 12 years, with a booster dose at age 16 
years.
• For children aged 2 months through 18 years with high-
risk conditions, see “Meningococcal conjugate ACWY 
vaccination of persons with high-risk conditions and 
other persons at increased risk” and “Meningococcal B 
vaccination of persons with high-risk conditions and other 
persons at increased risk of disease” below.
Catch-up vaccination:
• Administer Menactra or Menveo vaccine at age 13 through 
18 years if not previously vaccinated.
• If the first dose is administered at age 13 through 15 years, 
a booster dose should be administered at age 16 through 
18 years, with a minimum interval of at least 8 weeks 
between doses.
• If the first dose is administered at age 16 years or older, a 
booster dose is not needed.
• For other catch-up guidance, see Figure 2.
Clinical discretion:
• Young adults aged 16 through 23 years (preferred age 
range is 16 through 18 years) who are not at increased 
risk for meningococcal disease may be vaccinated with a 
2-dose series of either Bexsero (0, ≥1 month) or Trumenba 
(0, 6 months) vaccine to provide short-term protection 
against most strains of serogroup B meningococcal 
disease. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
• If the second dose of Trumenba is given at an interval of 
<6 months, a third dose should be given at least 6 months 
after the first dose; the minimum interval between the 
second and third doses is 4 weeks.
Meningococcal conjugate ACWY vaccination of persons 
with high-risk conditions and other persons at increased 
risk: 
Children with anatomic or functional asplenia (including 
sickle cell disease), children with HIV infection, or children 
with persistent complement component deficiency 
(includes persons with inherited or chronic deficiencies 
in C3, C5-9, properdin, factor D, factor H, or taking 
eculizumab [Soliris]):
 ▪ Menveo  
 ɱ Children who initiate vaccination at 8 weeks. Administer 
doses at ages 2, 4, 6, and 12 months.
 ɱ Unvaccinated children who initiate vaccination at 7 
through 23 months. Administer 2 primary doses, with 
the second dose at least 12 weeks after the first dose 
AND after the first birthday.
 ɱ Children 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 8 
weeks apart.
 ▪ MenHibrix
 ɱ Children who initiate vaccination at 6 weeks. Administer 
doses at ages 2, 4, 6, and 12 through 15 months.
 ɱ If the first dose of MenHibrix is given at or after age 12 
months, a total of 2 doses should be given at least 8 
weeks apart to ensure protection against serogroups 
C and Y meningococcal disease.For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
7. Influenza vaccines. (Minimum age: 6 months for inacti-
vated influenza vaccine [IIV], 18 years for recombinant 
influenza vaccine [RIV]) 
Routine vaccination:
• Administer influenza vaccine annually to all children 
beginning at age 6 months. For the 2016–17 season, 
use of live attenuated influenza vaccine (LAIV) is not 
recommended.
For children aged 6 months through 8 years:
• For the 2016–17 season, administer 2 doses (separated by 
at least 4 weeks) to children who are receiving influenza 
vaccine for the first time or who have not previously 
received ≥2 doses of trivalent or quadrivalent influenza 
vaccine before July 1, 2016. For additional guidance, 
follow dosing guidelines in the 2016–17 ACIP influenza 
vacci e rec mmendatio s (see MMWR August 26, 
2016;65(5):1-54, available at  
www.c c. ov/mmwr/volumes/65/rr/pdfs/rr6505.pdf).
• For the 2017–18 s ason follow dosing guidelines in the 
2017–18 ACIP influenza vaccine ecommendations.  
For perso s aged 9 years and older:
• Administer 1 dose.
8. Measl s, mumps, and ubella (MMR) vaccine. (Minimum 
age: 12 months for routine vaccin tion)
Routine vaccination:
• Administer a 2-dose series of MMR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered before age 4 years, provided at 
least 4 weeks have elapsed since the first dose.
• Administer 1 dose of MMR vaccine to infants aged 6 
through 11 months before departure from the United 
States for intern tional travel. These children should be 
revaccina ed with 2 doses of MMR vaccine, the first at age 
12 through 15 months (12 months if the hild remains in 
an area wh re disease risk is high), a d the second dose at 
leas  4 weeks later.
• Administer 2 doses of MMR vaccine to children aged 
12 months and older before departure from the United 
States fo  international travel. The first dose should be 
administered on or after age 12 months and the second 
dose at least 4 weeks later.
Catch-up vaccination:
• Ensure that all school-aged children and adolescents 
have had 2 doses of MMR vaccine; the minimum interval 
between the 2 doses is 4 weeks.  
9. Varicella (VAR) vaccine. (Minimum age: 12 months) 
Routine vaccination:
• Administer a 2-dose series of VAR vaccine at ages 12 
through 15 months and 4 through 6 years. The second 
dose may be administered before age 4 years, provided 
at least 3 months have elapsed since the first dose. If the 
second dose was administered at least 4 weeks after the 
first dose, it can be accepted as valid.
Catch-up va cination:
• Ensure that all persons aged 7 through 18 years without 
evidence of immunity (see MMWR 2007;56[No. RR-4], 
available at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf ) have 
2 doses of varicella vaccine.  For children aged 7 through 
12 years, the recommended minimum interval between 
doses is 3 months (if the second dose was administered 
at least 4 weeks after the first dose, it can be accepted as 
valid); for persons aged 13 years and older, the minimum 
interval between doses is 4 weeks.
10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Routine vaccination:
• Initiate the 2-dose HepA vaccine series at ages 12 through 
23 months; separate the 2 doses by 6 to 18 months.
• Children who have received 1 dose of HepA vaccine 
before age 24 months should receive a second dose 6 to 
18 months after the first dose.
• For any person aged 2 years and older who has not 
already received the HepA vaccine series, 2 doses of 
HepA vaccine separated by 6 to 18 months may be 
administered if immunity against hepatitis A virus 
infection is desired. 
Catch-up vaccination:
• The minimum interval between the 2 doses is 6 months. 
Special populations: 
• Ad i ister 2 doses of HepA vaccine at least 6 months apart 
to previously unvaccinated persons who live in areas where 
vaccination programs target older children, or who are at 
increased risk for infection.  This includes persons traveling 
to or working n countries that ave high or intermediate 
endemicity of infection; men having sex with men; users 
of inj ction and non-injection illicit drugs; persons who 
work with HAV-infected primates r with HAV in a research 
laboratory; persons with clotting-factor disorders; persons 
with chronic liver disease; and persons who anticipate 
cl se, p rson l contact (e.g., household or regular 
babysitting) with an international adoptee during the first 
60 days after arrival in the United States from a country 
with high or intermediate endemicity. The first dose should 
be administered as soon as the adoption is planned, ideally, 
2 or more weeks before the arrival of the adoptee.
11. Meningococcal vaccines. (Minimum ge: 6 weeks for 
Hib-MenCY [MenHibrix], 2 months for M ACWY-CRM 
[Menveo], 9 months for MenACWY-D [M nactra], 10 yea s 
for serogroup B meningococcal [MenB] va cine : MenB-
4C [Bexsero] and MenB-FHbp [Trumenba])
Routine vaccin tion:
• Administer a single dose of Me actra or Me ve  vaccin  
at age 11 through 12 years, with a booster dose at age 16 
ye rs.
• For children aged 2 months through 18 years with high-
risk conditions, see “Meningococcal conjugate ACWY 
vaccination of persons with high-risk conditions and 
other pe sons at increased risk” and “Meningococcal B 
vaccination of persons with high-risk conditions and other 
persons at increased risk of disease” below.
Catch-up vaccination:
• Administer Menactra or Menveo vaccine at age 13 through 
18 years if not previously vaccinated.
• If the first dose is administered at age 13 through 15 years, 
a booster dose should be administered at age 16 through 
18 years, with a minimum interval of at least 8 weeks 
between doses.
• If the first dose is administered at age 16 years or older, a 
booster dose is not needed.
• For other catch-up guidance, see Figure 2.
Clinical discretion:
• Young adults aged 16 through 23 years (preferred age 
range is 16 through 18 years) who are not at increased 
risk for meningococcal disease may be vaccinated with a 
2-dose series of either Bexsero (0, ≥1 month) or Trumenba 
(0, 6 months) vaccine to provide short-term protection 
against most strains of serogroup B meningococcal 
disease. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
• If the second dose of Trumenba is given at an interval of 
<6 months, a third dose should be given at least 6 months 
after the first dose; the minimum interval between the 
second and third doses is 4 weeks.
Meningococcal conjugate ACWY vaccination of persons 
with high-risk conditions and other persons at increased 
risk: 
Children with anatomic or functional asplenia (including 
sickle cell disease), children with HIV infection, or children 
with persistent complement component deficiency 
(includes persons with inherited or chronic deficiencies 
in C3, C5-9, properdin, factor D, factor H, or taking 
eculizumab [Soliris]):
 ▪ Menveo  
 ɱ Children who initiate vaccination at 8 weeks. Administer 
doses at ages 2, 4, 6, and 12 months.
 ɱ Unvaccinated children who initiate vaccination at 7 
through 23 months. Administer 2 primary doses, with 
the second dose at least 12 weeks after the first dose 
AND after the first birthday.
 ɱ Children 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 8 
weeks apart.
 ▪ MenHibrix
 ɱ Children who initi te vaccination at 6 weeks. Administer 
oses at ages 2, 4, 6, nd 12 through 15 months.
 ɱ If the first dose of MenHibrix is given at or after age 12 
months, a total of 2 doses should be given at least 8 
weeks apart to ensure protection against serogroups
C and Y meningococcal disease.For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
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 ▪ Menactra
 ɱ Children with anatomic or functional asplenia o  
HIV infection
 ʲ Children 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 
8 weeks apart. If Menactra is administered to a child 
with asplenia (including sickle cell disease) r HIV 
infection, do not administer Menactra until age 2 
years and at least 4 weeks after the completion of 
all PCV13 doses.
 ɱ Children with persistent complement component 
deficiency
 ʲ Children 9 through 23 months. Administer 2 primary 
doses at least 12 weeks apart.
 ʲ Children 24 months a d older who have not received 
a complete series. Administ r 2 primary doses at 
least 8 weeks apart.
 ɱ All igh-risk childre
 ʲ If Menactra is to b  administered to a child at high 
risk for m ningococcal disease, it is recommende  
that Menactra be given either before or at t e same 
time as DTaP.
Meningococcal B vaccination of persons with high-risk 
conditions and other persons at increased risk of disease:
Childr n with anatomic or functional asplenia (including 
sickle cell disease) or children with persistent complement 
compone t deficiency (includes persons with inherited or 
chronic deficiencies in C3, C5-9, properdin, factor D, factor 
H, r taking eculizumab [Soliris]):
 ▪ Bexsero or Trumenba
 ɱ Persons 10 years or older who have not received a com-
plete series. Admi ister a 2-dose series of Bexsero, with 
doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1–2 months 
after the first and the third dose at least 6 months 
after the first. The two MenB vaccines are not inter-
changeable; the same vaccine product must be used 
for all doses.
For children who travel to or reside in countries in which 
meningococcal disease is hyperendemic or epidemic, 
including countries in the African meningitis belt or the 
Hajj: 
 ▪ Administer an age-appropriate formulation and series of 
Menactra or Menveo for protection against serogroups A 
and W meningococcal disease. Prior receipt of MenHibrix 
is not sufficient for children traveling to the meningitis 
belt or the Hajj because it does not contain serogroups 
A or W.
For children at risk during an outbreak attributable to a 
vaccine serogroup:
 ▪ For serogroup A, C, W, or Y: Administer or complete an 
age- and formulation-appropriate series of MenHibrix, 
Menactra, or Menveo.
 ▪ For serogroup B: Administer a 2-dose series of Bexsero, 
with dos s at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1-2 months 
after t e first nd the thir  dose at least 6 months after 
the first. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
For MenACWY booster doses among persons with high-risk 
conditions, refer to MMWR 2013;62(RR02):1-22, at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm, 
MMWR June 20, 2014 / 63(24):527-530, at www.cdc.gov/
mmwr/pdf/wk/mm6324.pdf, and MMWR November 4, 2016 
/ 65(43):1189-1194, at www.cdc.gov/mmwr/volumes/65/
wr/pdfs/mm6543a3.pdf.
For other catch-up recommendations for these persons and 
complete information on use of meningococcal vaccines, 
including guidance related to vaccination of persons at 
increased risk of infection, see meningococcal MMWR 
publications, available at: www.cdc.gov/vaccines/hcp/acip-
recs/vacc-specific/mening.html.
12. Tetanus and diphtheria toxoids and acellular pertussis 
(Tdap) vaccine. (Minimum age: 10 years for both Boostrix 
and Adacel)
Routine vaccination: 
• Administer 1 dose of Tdap vaccine to all adolescents aged 
11 through 12 years.
• Tdap may be administered regardless of the interval since 
the last tetanus and diphtheria toxoid-containing vaccine.
• Administer 1 dose of Tdap vaccine to pregnant 
adolescents during each pregnancy (preferably during 
the early part of gestational weeks 27 through 36), 
regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
• Per ons aged 7 years and ld r who are not fully 
immu ized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up 
series; if additional doses are needed, use Td vaccine. For 
children 7 through 10 years who receive a dose of Tdap 
as part of the catch-up series, an adolescent Tdap vaccine 
dose at age 11 through 12 years may be administered.
• Persons aged 11 through 18 years who have not received 
Tdap vaccine should receive a dose, followed by tetanus 
and diphtheria toxoids (Td) booster doses every 10 years 
thereafter.
• Inadvertent doses of DTaP vaccine:
 ▪ If administered inadvertently to a child aged 7 through 
10 years, the dose may count as part of the catch-up 
series. This dose may count as the adolescent Tdap dose, 
or the child may receive a Tdap booster dose at age 11 
through 12 years.
 ▪ If administered inadvertently to an adolescent aged 11 
through 18 years, the dose should be counted as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
13. Human papillomavirus (HPV) vaccines.  (Minimum age: 9 
years for 4vHPV [Gardasil] and 9vHPV [Gardasil 9])  
Routine and catch-up vaccination:
• Administer a 2-dose series of HPV vaccine on a schedule 
of 0, 6-12 months to all adolescents aged 11 or 12 years.  
The vaccination series can start at age 9 years. 
• Administer HPV vaccine to all adolescents through 
age 18 years who were not previously adequately 
vaccinated. The number of recommended doses is 
based on age at administration of the first dose. 
• For persons initiating vaccination before age 15, the 
recommended immunization schedule is 2 doses of HPV 
vaccine at 0, 6-12 months. 
• For persons initiating vaccination at age 15 years or 
older, the recommended immunization schedule is 3 
doses of HPV vaccine at 0, 1–2, 6 months.
• A vaccine dose administered at a shorter interval should 
be readministered at the recommended interval. 
 ▪ In a 2-dose schedule of HPV vaccine, the minimum 
interval is 5 months between the first and second dose. 
If the second dose is administered at a shorter interval, 
a third dose should be administered a minimum of 
12 weeks after the second dose and a minimum of 5 
months after the first dose.
 ▪ In a 3-dose schedule of HPV vaccine, the minimum 
intervals are 4 weeks between the first and second dose, 
12 weeks between the second and third dose, and 5 
months between the first and third dose. If a vaccine 
dose is administered at a shorter interval, it should be 
readministered after another minimum interval has 
been met since the most recent dose.
Special populations:
• For children with history of sexual abuse or assault, 
administer HPV vaccine beginning at age 9 years. 
• Immunocompromised persons*, including those 
with human immunodeficiency virus (HIV) infection, 
should receive a 3-dose series at 0, 1–2, and 6 months, 
regardless of age at vaccine initiation.
• Note: HPV vaccination is not recommended during 
pregnancy, although there is no evidence that the 
vaccine poses harm. If a woman is found to be pregnant 
after initiating the vaccination series, no intervention is 
needed; the remaining vaccine doses should be delayed 
until after the pregnancy. Pregnancy testing is not 
needed before HPV vaccination.
*See MMWR December 16, 2016;65(49):1405-1408, 
available at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
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 ▪ Menactra
 ɱ Children with anatomic or functional asplenia or 
HIV infecti n
 ʲ Childr n 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 
8 weeks apart. If Menactra is administered to a child 
with asplenia (including sickle cell disease) or HIV 
infec ion, do not administer Menactra until age 2 
year and t least 4 weeks after the completion of 
all PCV13 doses.
 ɱ Children with persistent complement component 
deficiency
 ʲ Children 9 through 23 months. Administer 2 primary 
doses at least 12 weeks apart.
 ʲ Children 24 months and older who have not received 
a complete series. Administer 2 primary doses at 
least 8 weeks apart.
 ɱ All high-risk children
 ʲ If Menactra is to be administered to a child at high 
risk for meningococcal disease, it is recommended 
that Menactra be given either before or at the same 
time as DTaP.
Mening coccal B vaccination of persons with high-risk 
conditions and other persons at increased risk of disease:
Children with anatomic or functional asplenia (including 
sickle cell disease) or children with persistent complement 
component eficiency (includes persons with inherited or 
chronic deficienci s in C3, C5-9, properdin, factor D, factor 
H, or taking eculizumab [Soliris]):
 ▪ Bexsero or Trumenba
 ɱ Persons 10 years or older who have not received a com-
plete series. Administer a 2-dose series of Bexsero, with 
doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1–2 months 
after the first and the third dose at least 6 months 
after the first. The two MenB vaccines are not inter-
changeable; the same vaccine product must be used 
for all doses.
For children who travel to or reside in countries in which 
meningococcal disease is hyperendemic or epidemic, 
including countries in the Afric n meningitis belt or the 
Hajj: 
 ▪ Administer an age-appropriate formulation and series of 
Menactra or Menveo for protection against serogroups A 
and W meningococcal disease. Prior receipt of MenHibrix 
is not sufficient for children traveling to the meningitis 
belt or the Hajj because it does not contain serogroups 
A or W.
For children at risk during an outbreak attributable to a 
vaccine serogroup:
 ▪ For serogroup A, C, W, Y: Administer or complete an 
ag - and formulation-appropriate series of MenHibrix, 
Menactra, or Menveo.
 ▪ For serogroup B: Administer a 2-dose series of Bexsero, 
with doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1-2 months 
after the first and the third dose at least 6 months after 
the first. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
For MenACWY booster doses among persons with high-risk 
conditions, refer to MMWR 2013;62(RR02):1-22, at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm, 
MMWR June 20, 2014 / 63(24):527-530, at www.cdc.gov/
mmwr/pdf/wk/mm6324.pdf, and MMWR November 4, 2016 
/ 65(43):1189-1194, at www.cdc.gov/mmwr/volumes/65/
wr/pdfs/mm6543a3.pdf.
F r other catch-up recommendations for these persons and 
compl te information on use of me ingococcal vaccines, 
including guidance related o vaccination of persons at 
increased risk of infection, see meningococcal MMWR 
publicatio s, available at: www.cdc.gov/vaccines/hcp/acip-
recs/vacc-specific/mening.html.
12. Tetanus and diphtheria toxoids and acellular pertussis 
(Tdap) vaccine. (Minimum age: 10 years for both Boostrix 
and Adacel)
Routine vaccination: 
• Administer 1 dose of Tdap vaccine to all adolescents aged 
11 hrough 12 ye rs.
• Tdap may be admini tered regardless of the interval since 
the last tetanus and diphtheria toxoid-containing vaccine.
• Administer 1 dose of Tdap vaccine to pregnant 
adolescents during each pregnancy (preferably during 
the early part of gestational weeks 27 through 36), 
regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
• Persons aged 7 years and older who are not fully 
immunized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up 
seri s; if additi l doses are needed, use Td vaccine. For 
childre  7 through 10 years who receive a dose of Tdap 
as part of the catch-up series, an adolescent Tdap vaccine 
dose at age 11 through 12 years may be administered.
• Persons aged 11 through 18 years who have not received 
Tdap vaccine should receive a dose, followed by tetanus 
and diphtheria toxoids (Td) booster doses every 10 years 
thereafter.
• Inadvertent doses of DTaP vaccine:
 ▪ If administered inadvertently to a child aged 7 through 
10 years, the dose may count as part of the catch-up 
series. This dose may count as the adolescent Tdap dose, 
or the child may receive a Tdap booster dose at age 11 
through 12 years.
 ▪ If administered inadvertently to an adolescent aged 11 
through 18 years, the dose should be counted as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
13. Human papillomavirus (HPV) vaccines.  (Minimum age: 9 
years for 4vHPV [Gardasil] and 9vHPV [Gardasil 9])  
Routine and catch-up vaccination:
• Administer a 2-dose series of HPV vaccine on a schedule 
of 0, 6-12 months to all adolescents aged 11 or 12 years.  
The vaccination series can start at age 9 years. 
• Administer HPV vaccine to all adolescents through 
age 18 years who were not previously adequately 
vaccinated. The number of recommended doses is 
based on age at administration of the first dose. 
• For persons initiating vaccination before age 15, the 
recommended immunization schedule is 2 doses of HPV 
vaccine at 0, 6-12 months. 
• For persons initiating vaccination at age 15 years or 
older, the recommended immunization schedule is 3 
doses of HPV vaccine at 0, 1–2, 6 months.
• A vaccine dose administered at a shorter interval should 
be readministered at the recommended interval. 
 ▪ In a 2-dose schedule of HPV vaccine, the minimum 
interval is 5 months between the first and second dose. 
If the second dose is administered at a shorter interval, 
a third dose should be administered a minimum of 
12 weeks after the second dose and a minimum of 5 
months after the first dose.
 ▪ In a 3-dose schedule of HPV vaccine, the minimum 
intervals are 4 weeks between the first and second dose, 
12 weeks between the second and third dose, and 5 
months between the first and third dose. If a vaccine 
dose is administered at a shorter interval, it should be 
readministered after another minimum interval has 
been met since the most recent dose.
Special populations:
• For children with history of sexual abuse or assault, 
administer HPV vaccine beginning at age 9 years. 
• Immunocompromised persons*, including those 
with human immunodeficiency virus (HIV) infection, 
should receive a 3-dose series at 0, 1–2, and 6 months, 
regardless of age at vaccine initiation.
• Note: HPV vaccination is not recommended during 
pregnancy, although there is no evidence that the 
vaccine poses harm. If a woman is found to be pregnant 
after initiating the vaccination series, no intervention is 
needed; the remaining vaccine doses should be delayed 
until after the pregnancy. Pregnancy testing is not 
needed before HPV vaccination.
*See MMWR December 16, 2016;65(49):1405-1408, 
available at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
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 ▪ Men tra
 ɱ Childr n with anatomic or functional asplenia or 
HIV infecti n
 ʲ Children 24 months and older who have not received a 
complete series. Administer 2 primary doses at least 
8 weeks apart. If Menactra is administered to a child 
with asplenia (including sickle cell disease) or HIV 
infection, do not administer Menactra until age 2 
years and at least 4 weeks after the completion of 
all PCV13 doses.
 ɱ Children with persistent complement component 
deficiency
 ʲ Children 9 through 23 months. Administer 2 primary 
doses at least 12 weeks apart.
 ʲ Children 24 months and older who have not received 
a complete series. Administer 2 primary doses at 
least 8 weeks apart.
 ɱ All high-risk children
 ʲ If Menactra is to be administered to a child at high 
risk for meningococcal disease, it is recommended 
that Menactra be given either before or at the same 
time as DTaP.
Meningococcal B vaccination of persons with high-risk 
conditions and other persons at increased risk of disease:
Children with anatomic or functional asplenia (including 
sickle cell disease) or children with persistent complement 
component deficiency (includes persons with inherited or 
chronic deficiencies in C3, C5-9, properdin, factor D, factor 
H, or taking eculizumab [Soliris]):
 ▪ Bexsero or Trumenba
 ɱ Persons 10 years or older who have not received a com-
plete series. Administer a 2-dose series of Bexsero, with 
doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1–2 months 
after the first and the third dose at least 6 months 
after t e first. The two MenB vaccines are not inter-
changeable; the same vaccine product must be used 
for all doses.
For children who travel to or reside in countries in which 
me ingococcal disease s hyperendemic or epidemic, 
i cluding countries in the African meningitis belt or the 
Hajj: 
 ▪ Administer an age-appropriate formulation and series of 
Menactra or Menveo for protection against serogroups A 
and W m ningococcal disease. Prior receipt of MenHibrix 
i  not sufficient for children traveling to the meningitis 
belt or the Hajj because it does not contain serogroups 
A or W.
For children at risk during an outbreak attributable to a 
vaccine serogroup:
 ▪ For serogroup A, C, W, or Y: Administer or complete an 
age- and formulation-appropriate series of MenHibrix, 
Menactra, or Menveo.
 ▪ For serogroup B: Administer a 2-dose series of Bexsero, 
with doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1-2 months 
after the first and the third dose at least 6 months after 
the first. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
For MenACWY booster doses among persons with high-risk 
conditions, refer to MMWR 2013;62(RR02):1-22, at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm, 
MMWR June 20, 2014 / 63(24):527-530, at www.cdc.gov/
mmwr/pdf/wk/mm6324.pdf, and MMWR November 4, 2016 
/ 65(43):1189-1194, at www.cdc.gov/mmwr/volumes/65/
wr/pdfs/m 6543a3.pdf.
For other catch-up recommendations for these persons and 
compl te informatio  on use of meningococcal vaccines, 
including guidance related to vaccination of persons at 
increased risk of infection, see meningococcal MMWR 
publicatio s, available at: www. dc.gov/vaccines/hcp/acip-
recs/vacc-specific/mening.html.
12. Tetanus and diphtheria toxoids and acellular pertussis 
(Tdap) vaccine. (Minimum age: 10 years for both Boostrix 
and Adacel)
Routine vaccination: 
• Administer 1 dose of Tdap vaccine to all adolescents aged 
11 through 12 years.
• Tdap may be administered regardless of the interval since 
the last tetanus and diphtheria toxoid-containing vaccine.
• Administer 1 dose of Td p vaccine to pregnant 
adolescents during each pregnancy (preferably during 
the early part of gestational weeks 27 through 36), 
regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
• Persons aged 7 years and older who are not fully 
immunized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up 
series; if additional doses are needed, use Td vaccine. For 
children 7 through 10 years who receive a dose of Tdap 
as part of the catch-up series, an adolescent Tdap vaccine 
d se at age 11 through 12 years may be administered.
• P r ons aged 11 through 18 years who have not received 
Tdap vaccine should receive a dose, followed by tetanus 
and diphtheria toxoids (Td) booster doses every 10 years 
thereafter.
• Inadvertent doses of DTaP vaccine:
 ▪ If administered inadvertently to a child aged 7 through 
10 years, the dose may count as part of the catch-up 
series. This dose may count as the adolescent Tdap dose, 
or the child may receive a Tdap booster dose at age 11 
through 12 years.
 ▪ If administered inadvertently to an adolescent aged 11 
through 18 years, the dose should be counted as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
13. Human papillomavirus (HPV) vaccines.  (Minimum age: 9 
years for 4vHPV [Gardasil] and 9vHPV [Gardasil 9])  
Routine and catch-up vaccination:
• Administer a 2-dose series of HPV vaccine on a schedule 
of 0, 6-12 months to all adolescents aged 11 or 12 years.  
The vaccination series can start at age 9 years. 
• Administer HPV vaccine to all adolescents through 
age 18 years who were not previously adequately 
vaccinated. The number of recommended doses is 
based on age at administration of the first dose. 
• For persons initiating vaccination before age 15, the 
recommended immunization schedule is 2 doses of HPV 
vaccine at 0, 6-12 months. 
• For persons initiating vaccination at age 15 years or 
older, the recommended immunization schedule is 3 
doses of HPV vaccine at 0, 1–2, 6 months.
• A vaccine dose administered at a shorter interval should 
be readministered at the recommended interval. 
 ▪ In a 2-dose schedule of HPV vaccine, the minimum 
interval is 5 months between the first and second dose. 
If the second dose is administered at a shorter interval, 
a third dose should be administered a minimum of 
12 weeks after the second dose and a minimum of 5 
months after the first dose.
 ▪ In a 3-dose schedule of HPV vaccine, the minimum 
intervals are 4 weeks between the first and second dose, 
12 weeks between the second and third dose, and 5 
months between the first and third dose. If a vaccine 
dose is administered at a shorter interval, it should be 
readministered after another minimum interval has 
been met since the most recent dose.
Special populations:
• For children with history of sexual abuse or assault, 
administer HPV vaccine beginning at age 9 years. 
• Immunocompromised persons*, including those 
with human immunodeficiency virus (HIV) infection, 
should receive a 3-dose series at 0, 1–2, and 6 months, 
regardless of age at vaccine initiation.
• Note: HPV vaccination is not recommended during 
pregnancy, although there is no evidence that the 
vaccine poses harm. If a woman is found to be pregnant 
after initiating the vaccination series, no intervention is 
needed; the remaining vaccine doses should be delayed 
until after the pregnancy. Pregnancy testing is not 
needed before HPV vaccination.
*See MMWR December 16, 2016;65(49):1405-1408, 
available at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
For further guidance on the use of the vaccine  mentio ed below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
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 ▪ Menactra
 ɱ Children with anatomic or functional asplenia or 
HIV infection
 ʲ Children 24 months an  older who have not received a 
complete series. Administer 2 primary doses at least 
8 weeks apart. If Menactra is administered to a child 
with aspl nia (including sickle cell disease) or HIV 
infection, do not administer Menactra until age 2 
ye rs and at least 4 weeks after the completion of 
all PCV13 doses.
 ɱ Children with persistent complement component 
deficiency
 ʲ Children 9 through 23 months. Administer 2 primary 
doses at least 12 weeks apart.
 ʲ Children 24 months and older who have n t received 
a complete series. Administer 2 primary doses at 
least 8 weeks apart.
 ɱ All high-risk children
 ʲ If Menac ra is to b administered to a child at high 
risk for meningococcal disease, it is recommended 
that Menactra be iven either before or at the same 
time as DTaP.
Meningococc l B v ccination of persons with high-risk 
conditions and other persons at increased risk of disease:
Children with anatomic or functional asplenia (including 
sickle cell disease) or children with persistent complement 
component deficiency (includes persons with inherited or 
chronic deficiencies in C3, C5-9, properdin, factor D, factor 
H, or taking eculizumab [Soliris]):
 ▪ Bexsero or Trumenba
 ɱ Persons 10 years or older who have not received a com-
plete series. Administer a 2-dose series of Bexsero, with 
doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1–2 months 
after the first and the third dose at least 6 months 
after the first. The two MenB vaccines are not inter-
changeable; the same vaccine product must be used 
for all d ses.
For children who travel to or reside in countries in which 
meningococcal disease is hyperendemic or epidemic, 
including countries in the African meningitis belt or the 
Hajj: 
 ▪ Administer an age-appropriate formulation and series of 
Menactra or Menveo for protection against serogroups A 
and W meningococcal disease. Prior receipt of MenHibrix 
is not sufficient for children traveling to the meningitis 
belt or the Hajj because it does not contain serogroups 
A or W.
For children at risk during an outbreak attributable to a 
vaccine serogroup:
 ▪ For ser group A, C, W, or Y: Administer or complete an 
age- and formulation-appropriate series of MenHibrix, 
Menactra, or Menveo.
 ▪ For serogroup B: Administer a 2-dose series of Bexsero, 
with doses at least 1 month apart, or a 3-dose series of 
Trumenba, with the second dose at least 1-2 months 
after the first and the third dose at least 6 months after 
the first. The two MenB vaccines are not interchangeable; 
the same vaccine product must be used for all doses.
For MenACWY bo ster doses among persons with high-risk 
conditions, efer to MMWR 2013;62(RR02):1-22, at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm, 
MMWR June 20, 2014 / 63(24):527-530, at www.cdc.gov/
mmw /pdf/wk/mm6324.pdf, and MMWR November 4, 2016 
/ 65(43):1189-1194, at www.cdc.gov/mmwr/volumes/65/
wr/pdfs/m 6543a3.pdf.
For other catch-up recommendations for these persons and 
complete information on use of meningococcal vaccines, 
including guidance related to vaccination of persons at 
increased risk of infection, see meningococcal MMWR 
publications, available at: www.cdc.gov/vaccines/hcp/acip-
recs/vacc-specific/mening.html.
12. Tetanus and diphth ria toxo ds and acellular pertussis 
(Tdap) vaccine. (Minimum age: 10 y ars for both Boostrix 
and Adacel)
Routine vaccination: 
• Administer 1 dose of Tdap vaccine to all adolescents aged 
11 through 12 years.
• Tdap may be administered regardless of the interval since 
the last tetanus and diphtheria toxoid-containing vaccine.
• Administer 1 dose of Tdap vaccine to pregnant 
adolescents during each pregnancy (preferably during 
the early part of gestational weeks 27 through 36), 
regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
• Persons aged 7 years and older wh  are not fully 
immunized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up 
series; if additional doses are needed, use Td vaccine. For 
child en 7 through 10 years who receive a dose of Tdap 
as p rt of the catch-up series, an adolescent Tdap vaccine 
dose at age 11 through 12 years may be administered.
• Persons aged 11 through 18 years who have not received 
Tdap vaccine should receive a dose, followed by tetanus 
and diphtheria toxoids (Td) booster doses every 10 years 
thereafter.
• Inadvertent doses of DTaP vaccine:
 ▪ If administered inadvertently to a child aged 7 through 
10 years, the dose may count as part of the catch-up 
series. Thi  dose may count as the adolescent Tdap dose, 
or the child may receive a Tdap booster dose at age 11 
through 12 years.
 ▪ If a ministered inadvertently to an adolescent aged 11 
through 18 years, the dose should be counted as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
13. Human papillomavirus (HPV) vaccines.  (Minimum age: 9 
years for 4vHPV [Gardasil] and 9vHPV [Gardasil 9])  
Routine and catch-up vaccination:
• Administer a 2-dose series of HPV vaccine on a schedule 
of 0, 6-12 months to all adolescents aged 11 or 12 years.  
The vaccination series can start at age 9 years. 
• Administer HPV vaccine to all adolescents through 
age 18 years who were not previously adequately 
vaccinated. The number of recommended doses is 
based on age at administration of the first dose. 
• For persons initiating vaccination before age 15, the 
recommended immunization schedule is 2 doses of HPV 
vaccine at 0, 6-12 months. 
• For persons initiating vaccination at age 15 years or 
older, the recommended immunization schedule is 3 
doses of HPV vaccine at 0, 1–2, 6 months.
• A vaccine dose administered at a shorter interval should 
be readministered at the recommended interval. 
 ▪ In a 2-dose schedule of HPV vaccine, the minimum 
interval is 5 months between the first and second dose. 
If the second dose is administered at a shorter interval, 
a third dose should be administered a minimum of 
12 weeks after the second dose and a minimum of 5 
months after the first dose.
 ▪ In a 3-dose schedule of HPV vaccine, the minimum 
intervals are 4 weeks between the first and second dose, 
12 weeks between the second and third dose, and 5 
months between the first and third dose. If a vaccine 
dose is administered at a shorter interval, it should be 
readministered after another minimum interval has 
been met since the most recent dose.
Special populations:
• For children with history of sexual abuse or assault, 
administer HPV vaccine beginning at age 9 years. 
• Immunocompromised persons*, including those 
with human immunodeficiency virus (HIV) infection, 
should receive a 3-dose series at 0, 1–2, and 6 months, 
regardless of age at vaccine initiation.
• Note: HPV vaccination is not recommended during 
pregnancy, although there is no evidence that the 
vaccine poses harm. If a woman is found to be pregnant 
fter initiating the vaccination s ri s, no intervention is 
needed; the remaining vaccine d ses hould be delayed 
until aft r the pregnancy. Pregnancy testing is not 
ne ded before HPV vaccinatio .
*S e MMWR December 16, 2016;65(49):1405-1408, 
available at www.cdc.g v/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
